# Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron Deficiency

> **NCT07643818** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Government of Jersey** · enrollment: 150 (estimated)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction (HFpEF

## Interventions

- **DRUG:** Ferric Derisomaltose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07643818
- **Lead sponsor:** Government of Jersey
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-06-19
- **Primary completion:** 2029-07
- **Final completion:** 2029-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07643818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07643818, "Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron Deficiency". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07643818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*